Repurposing G-CSF (Filgrastim) in Long-Time Bone-Marrow Stem Cell Mobilization for Treating Neurodegenerative Disorders like ALS

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

Header Abstract Content Author and article information References Comments

Record: found
Abstract: found
Conference Proceedings: found

Is Open Access

Repurposing G-CSF (Filgrastim) in Long-Time Bone-Marrow Stem Cell Mobilization for Treating Neurodegenerative Disorders like ALS

Published

conference-abstract

Author(s): Ulrich Bogdahn ¹ ^, , Jörg Dietrich ² , Jochen Grassinger ³ , Friedrich Gause ⁴ , Marlene Tahedl ⁵ , Siw Johannesen ⁶

Publication date (Electronic, epreprint): 3 May 2024

Journal: RExPO24 Conference

Publisher: REPO4EU

Conference name: RExPO24

Conference date: 3-5 July 2024

Keywords: Neurodegeneration, ALS - Amyotrophic Lateral Sclerosis, GCSF/Filgrastim, Hematopoietic Stem Cell Mobilization, Biomarker Panel, Bioinformatics, Disease Modelling, Individualized Therapy in Neurodegeneration

Bookmark

Abstract

Velvio therapeutics aim at CNS reconstitution to renew stem cell populations in bone marrow, muscle and CNS, to reactivate normal cell functions (anti-senescence), to reactivate autophagy and normalize immune communication, to enhance stem cell friendly milieu (extracellular matrix), and to reverse scarring and fibrosis. Velvio has developed selective biomarkers to monitor regained functionalities and to bridge the time gap between therapy and recovery - these include MRI imaging, inflammatory cyto- and chemo/kines, and stem cell markers in peripheral blood. ALS (Amyotrophic Lateral Sclerosis) is a grave disease with still limited treatment options and a median survival of approx. 16 to 24 months after diagnosis. Long-time pulsed G-CSF - BM stem cell mobilization is safe ¹ and highly effective ² in ALS: Clinical pilot data in N=36 ALS patients revealed significant slowing of disease progression and significantly increased survival. Disease modelling and a biomarker panel identified and validated 15 long-time survivors with median OS of 3.8 yrs from start of treatment and a very limited disease progression of -0,12 ALS-FRS-R loss / month with G-CSF therapy in contrast to -0,9 ALS-FRS-R loss / month with best standard care. Among many other modes of action for G-CSF, it was nicely shown ³ that bone marrow cells drive central nervous system regeneration, here after radiation injury. With this impressive therapeutic potential in mind, we want to initiate a prospective pivotal adaptive clinical trial of G-CSF to achieve regulatory approval for ‘early’ ALS patients. The architecture of such a trial and the related expenditure will be discussed in the light of the high unmet medical need and the opportunity of using a ‘repurposed’ therapeutic compound employed over decades in hemato-oncology and intensive care medicine. Velvio believes that healthcare investors and regulatory authorities should not miss the opportunity for such a shortcut to establish a very efficacious new treatment option for desperate ALS patients.

Content

Author and article information

Conference

Title: RExPO24 Conference

Publisher: REPO4EU

Publication date (Electronic, epreprint): 3 May 2024

Affiliations

[1 ] Velvio GmbH, Am Biopark 11, 93055 Regensburg, Germany;

[2 ] Deptm. Neurology, Div. Neuro-Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA02114, USA ( https://ror.org/002pd6e78)

[3 ] Department of Hematology and Oncology, Comp. Brothers Hospital St. Elisabeth, 94315 Straubing, Germany ( https://ror.org/02e560b93)

[4 ] BGM Associates, Winkler Str 11, 10664 Berlin, Germany;

[5 ] Dept. Radiology, Section Neuroradiology, TUM Munich, Ismaningerstr.22, 82675 Munich, Germany ( https://ror.org/02kkvpp62)

[6 ] Berufsgenossenschaftliche Unfallklinik Murnau, Prof.-Küntscher-Str. 8, 82418 Murnau;

Author notes

[* ]Email: uli.bogdahn@ 123456ukr.de .

Author information

Ulrich Bogdahn https://orcid.org/0000-0003-0826-7482

Jörg Dietrich https://orcid.org/0000-0001-8291-0136

Friedrich Gause https://orcid.org/0009-0001-1604-7992

Marlene Tahedl https://orcid.org/0000-0003-1762-4824

Article

DOI: 10.58647/REXPO.24000052.v1

SO-VID: 6e3d198f-1907-4db6-9aea-9a1e5780f768

License:

This work has been published open access under Creative Commons Attribution License CC BY 4.0 , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Conditions, terms of use and publishing policy can be found at www.scienceopen.com .

Conference name: RExPO24

Conference number: 3

Conference location: Munich, Germany

Conference date: 3-5 July 2024

History

Date received : 3 May 2024

Product

REPO4EU

Funding

Funded by: funder-id , BMBF, Berlin;

References

Grassinger Jochen, Khomenko Andrei, Hart Christina, Baldaranov Dobri, Johannesen Siw W., Mueller Gunnar, Schelker Roland, Schulte-Mattler Wilhelm, Andreesen Reinhard, Bogdahn Ulrich. Safety and feasibility of long term administration of recombinant human granulocyte-colony stimulating factor in patients with amyotrophic lateral sclerosis. Cytokine. Vol. 67(1):21–28. 2014. Elsevier BV. [Cross Ref]
Johannesen Siw, Huie J. Russell, Budeus Bettina, Peters Sebastian, Wirth Anna M., Iberl Sabine, Kammermaier Tina, Kobor Ines, Wirkert Eva, Küspert Sabrina, Tahedl Marlene, Grassinger Jochen, Pukrop Tobias, Schneider Armin, Aigner Ludwig, Schulte-Mattler Wilhelm, Schuierer Gerhard, Koch Winfried, Bruun Tim-Henrik, Ferguson Adam R., Bogdahn Ulrich. Modeling and Bioinformatics Identify Responders to G-CSF in Patients With Amyotrophic Lateral Sclerosis. Frontiers in Neurology. Vol. 12:2021. Frontiers Media SA. [Cross Ref]
Dietrich Jorg, Baryawno Ninib, Nayyar Naema, Valtis Yannis K., Yang Betty, Ly Ina, Besnard Antoine, Severe Nicolas, Gustafsson Karin U., Andronesi Ovidiu C., Batchelor Tracy T., Sahay Amar, Scadden David T.. Bone marrow drives central nervous system regeneration after radiation injury. Journal of Clinical Investigation. Vol. 128(1):281–293. 2017. American Society for Clinical Investigation. [Cross Ref]

Comments

Comment on this article

[1] Grassinger Jochen, Khomenko Andrei, Hart Christina, Baldaranov Dobri, Johannesen Siw W., Mueller Gunnar, Schelker Roland, Schulte-Mattler Wilhelm, Andreesen Reinhard, Bogdahn Ulrich. Safety and feasibility of long term administration of recombinant human granulocyte-colony stimulating factor in patients with amyotrophic lateral sclerosis. Cytokine. Vol. 67(1):21–28. 2014. Elsevier BV. [Cross Ref]

[2] Johannesen Siw, Huie J. Russell, Budeus Bettina, Peters Sebastian, Wirth Anna M., Iberl Sabine, Kammermaier Tina, Kobor Ines, Wirkert Eva, Küspert Sabrina, Tahedl Marlene, Grassinger Jochen, Pukrop Tobias, Schneider Armin, Aigner Ludwig, Schulte-Mattler Wilhelm, Schuierer Gerhard, Koch Winfried, Bruun Tim-Henrik, Ferguson Adam R., Bogdahn Ulrich. Modeling and Bioinformatics Identify Responders to G-CSF in Patients With Amyotrophic Lateral Sclerosis. Frontiers in Neurology. Vol. 12:2021. Frontiers Media SA. [Cross Ref]

[3] Dietrich Jorg, Baryawno Ninib, Nayyar Naema, Valtis Yannis K., Yang Betty, Ly Ina, Besnard Antoine, Severe Nicolas, Gustafsson Karin U., Andronesi Ovidiu C., Batchelor Tracy T., Sahay Amar, Scadden David T.. Bone marrow drives central nervous system regeneration after radiation injury. Journal of Clinical Investigation. Vol. 128(1):281–293. 2017. American Society for Clinical Investigation. [Cross Ref]

Abstract submission is now open for RExPO25, the 4th International Conference on Systems Medicine, AI & Drug Repurposing. Submit your proposal for a talk or poster and join us in Barcelona, Spain, September 24-26, 2025.

Deadline for abstracts is June 30, 2025

Repurposing G-CSF (Filgrastim) in Long-Time Bone-Marrow Stem Cell Mobilization for Treating Neurodegenerative Disorders like ALS

Conference

Affiliations

Author notes

Author information

Article

History

Product

Funding

Categories

Comment on this article

Abstract submission is now open for RExPO25, the 4^th International Conference on Systems Medicine, AI & Drug Repurposing. Submit your proposal for a talk or poster and join us in Barcelona, Spain, September 24-26, 2025.